Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medically Uninsured | 5 | 2017 | 107 | 2.650 |
Why?
|
| Emergency Service, Hospital | 9 | 2020 | 1258 | 1.910 |
Why?
|
| Emergency Medicine | 3 | 2018 | 159 | 1.490 |
Why?
|
| Insurance Coverage | 3 | 2017 | 275 | 1.050 |
Why?
|
| Medicaid | 3 | 2017 | 306 | 1.030 |
Why?
|
| Patient Transfer | 2 | 2017 | 139 | 1.000 |
Why?
|
| Diagnostic Errors | 3 | 2020 | 518 | 0.850 |
Why?
|
| Health Expenditures | 3 | 2017 | 202 | 0.730 |
Why?
|
| Aftercare | 3 | 2017 | 251 | 0.730 |
Why?
|
| Medical Overuse | 2 | 2018 | 51 | 0.720 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2017 | 108 | 0.700 |
Why?
|
| Electronic Health Records | 3 | 2020 | 854 | 0.660 |
Why?
|
| Orthopedics | 3 | 2017 | 80 | 0.650 |
Why?
|
| Emergency Medical Services | 3 | 2020 | 470 | 0.600 |
Why?
|
| Patient Discharge | 3 | 2017 | 699 | 0.600 |
Why?
|
| Deinstitutionalization | 1 | 2017 | 4 | 0.600 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2017 | 22 | 0.580 |
Why?
|
| Reimbursement Mechanisms | 1 | 2017 | 76 | 0.550 |
Why?
|
| Wounds and Injuries | 2 | 2017 | 441 | 0.540 |
Why?
|
| Stroke Rehabilitation | 1 | 2016 | 62 | 0.540 |
Why?
|
| Health Information Exchange | 1 | 2016 | 13 | 0.540 |
Why?
|
| Safety-net Providers | 1 | 2016 | 55 | 0.500 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 536 | 0.490 |
Why?
|
| Urinary Tract Infections | 2 | 2016 | 348 | 0.490 |
Why?
|
| Health Policy | 1 | 2017 | 278 | 0.480 |
Why?
|
| Mental Health Services | 1 | 2017 | 258 | 0.470 |
Why?
|
| Medicare | 2 | 2017 | 926 | 0.470 |
Why?
|
| Choice Behavior | 1 | 2016 | 207 | 0.470 |
Why?
|
| Appendicitis | 1 | 2016 | 177 | 0.470 |
Why?
|
| Hypokalemia | 1 | 2014 | 61 | 0.450 |
Why?
|
| Brain Ischemia | 1 | 2016 | 311 | 0.450 |
Why?
|
| Gastroenteritis | 1 | 2016 | 352 | 0.440 |
Why?
|
| Information Dissemination | 1 | 2016 | 269 | 0.440 |
Why?
|
| Program Evaluation | 1 | 2016 | 602 | 0.430 |
Why?
|
| Potassium | 1 | 2014 | 328 | 0.420 |
Why?
|
| United States | 11 | 2024 | 15891 | 0.420 |
Why?
|
| Abdominal Pain | 1 | 2015 | 378 | 0.420 |
Why?
|
| Hyperkalemia | 1 | 2014 | 80 | 0.420 |
Why?
|
| Quality of Health Care | 1 | 2017 | 620 | 0.400 |
Why?
|
| Patient Readmission | 1 | 2016 | 572 | 0.390 |
Why?
|
| Referral and Consultation | 1 | 2017 | 933 | 0.390 |
Why?
|
| Hospitalization | 2 | 2018 | 2169 | 0.380 |
Why?
|
| Diabetes Mellitus | 3 | 2016 | 1047 | 0.380 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 831 | 0.350 |
Why?
|
| Mental Disorders | 1 | 2018 | 881 | 0.350 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2015 | 5581 | 0.350 |
Why?
|
| Quality Improvement | 1 | 2017 | 913 | 0.330 |
Why?
|
| Heart Arrest | 1 | 2014 | 380 | 0.330 |
Why?
|
| Asthma | 1 | 2016 | 893 | 0.310 |
Why?
|
| Odds Ratio | 3 | 2017 | 2311 | 0.290 |
Why?
|
| Mass Screening | 1 | 2016 | 1554 | 0.280 |
Why?
|
| Lung Neoplasms | 11 | 2015 | 12040 | 0.280 |
Why?
|
| Radiation Oncology | 1 | 2012 | 558 | 0.280 |
Why?
|
| Texas | 4 | 2018 | 6452 | 0.260 |
Why?
|
| Health Care Reform | 2 | 2017 | 64 | 0.260 |
Why?
|
| Pneumonectomy | 5 | 2013 | 862 | 0.230 |
Why?
|
| Insurance, Health | 2 | 2016 | 262 | 0.230 |
Why?
|
| Cost Savings | 1 | 2024 | 123 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2015 | 10400 | 0.220 |
Why?
|
| HIV Infections | 1 | 2016 | 2158 | 0.220 |
Why?
|
| Humans | 31 | 2024 | 271093 | 0.210 |
Why?
|
| Male | 19 | 2024 | 128484 | 0.200 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 4326 | 0.200 |
Why?
|
| Middle Aged | 16 | 2018 | 90524 | 0.200 |
Why?
|
| Forecasting | 2 | 2015 | 702 | 0.180 |
Why?
|
| Lung | 1 | 2012 | 3288 | 0.180 |
Why?
|
| Adult | 13 | 2024 | 82174 | 0.180 |
Why?
|
| Databases, Factual | 2 | 2018 | 2261 | 0.180 |
Why?
|
| Aged | 15 | 2018 | 73550 | 0.180 |
Why?
|
| Logistic Models | 2 | 2018 | 3445 | 0.170 |
Why?
|
| Female | 19 | 2024 | 149120 | 0.170 |
Why?
|
| Criminal Law | 1 | 2017 | 12 | 0.150 |
Why?
|
| Trauma Severity Indices | 1 | 2017 | 94 | 0.150 |
Why?
|
| Retrospective Studies | 11 | 2017 | 39951 | 0.140 |
Why?
|
| Risk Factors | 8 | 2016 | 17911 | 0.140 |
Why?
|
| Refusal to Treat | 1 | 2017 | 13 | 0.140 |
Why?
|
| Fees and Charges | 1 | 2017 | 13 | 0.140 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 12 | 0.140 |
Why?
|
| Ambulances | 1 | 2016 | 25 | 0.140 |
Why?
|
| Diagnosis-Related Groups | 1 | 2016 | 29 | 0.140 |
Why?
|
| Organizational Innovation | 1 | 2017 | 62 | 0.140 |
Why?
|
| Patient Simulation | 1 | 2017 | 47 | 0.140 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2011 | 417 | 0.130 |
Why?
|
| Appointments and Schedules | 1 | 2017 | 96 | 0.130 |
Why?
|
| Uncompensated Care | 1 | 2016 | 11 | 0.130 |
Why?
|
| Adolescent | 4 | 2018 | 32784 | 0.130 |
Why?
|
| Gallbladder Diseases | 1 | 2015 | 47 | 0.130 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 99 | 0.130 |
Why?
|
| Confidentiality | 1 | 2016 | 119 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2015 | 175 | 0.120 |
Why?
|
| Lost to Follow-Up | 1 | 2014 | 32 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 2403 | 0.120 |
Why?
|
| Program Development | 1 | 2016 | 259 | 0.120 |
Why?
|
| Urban Population | 1 | 2016 | 280 | 0.120 |
Why?
|
| Potassium Chloride | 1 | 2014 | 65 | 0.120 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 264 | 0.110 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 249 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 431 | 0.110 |
Why?
|
| Bone Diseases | 1 | 2014 | 143 | 0.110 |
Why?
|
| Public Health | 1 | 2016 | 296 | 0.110 |
Why?
|
| Patient Safety | 1 | 2018 | 612 | 0.110 |
Why?
|
| Diabetes Complications | 2 | 2013 | 307 | 0.110 |
Why?
|
| Cognition | 1 | 2018 | 970 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 547 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2016 | 631 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 601 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 2051 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1270 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2014 | 605 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 98 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2016 | 1236 | 0.090 |
Why?
|
| Biocompatible Materials | 1 | 2011 | 202 | 0.090 |
Why?
|
| Lymphatic Metastasis | 4 | 2015 | 4969 | 0.090 |
Why?
|
| Mediastinum | 1 | 2012 | 276 | 0.090 |
Why?
|
| Young Adult | 3 | 2018 | 22293 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 5938 | 0.080 |
Why?
|
| Age Factors | 2 | 2016 | 5458 | 0.080 |
Why?
|
| Collagen | 1 | 2011 | 723 | 0.080 |
Why?
|
| Myocardium | 1 | 2014 | 1175 | 0.080 |
Why?
|
| Stroke | 1 | 2016 | 1061 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2014 | 1147 | 0.080 |
Why?
|
| Aged, 80 and over | 7 | 2016 | 31079 | 0.070 |
Why?
|
| Breast Implants | 1 | 2011 | 375 | 0.070 |
Why?
|
| Hypertension | 1 | 2016 | 1588 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 2272 | 0.070 |
Why?
|
| Ferric Compounds | 1 | 2007 | 77 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2012 | 4006 | 0.070 |
Why?
|
| Neoplasm Staging | 5 | 2013 | 14020 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2012 | 2033 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 4503 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 1761 | 0.060 |
Why?
|
| Patient Selection | 1 | 2013 | 2032 | 0.060 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2011 | 742 | 0.060 |
Why?
|
| Mammaplasty | 1 | 2011 | 714 | 0.060 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 2068 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3081 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2016 | 6780 | 0.060 |
Why?
|
| Antibodies | 1 | 2007 | 806 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2663 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 1344 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2013 | 1384 | 0.060 |
Why?
|
| Image Enhancement | 1 | 2007 | 553 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8709 | 0.050 |
Why?
|
| Time Factors | 1 | 2016 | 12991 | 0.050 |
Why?
|
| Contrast Media | 1 | 2007 | 1500 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2016 | 17095 | 0.040 |
Why?
|
| Safety Management | 1 | 2020 | 135 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 5238 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 5317 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2011 | 5102 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 902 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 15282 | 0.040 |
Why?
|
| SEER Program | 2 | 2011 | 1052 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2011 | 5679 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2011 | 9290 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 3953 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 100 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 434 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 1567 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 310 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 7900 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2013 | 33808 | 0.020 |
Why?
|
| Propensity Score | 1 | 2013 | 772 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 462 | 0.020 |
Why?
|
| Survival Rate | 2 | 2013 | 12535 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 880 | 0.020 |
Why?
|
| Particle Size | 1 | 2007 | 188 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 1430 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 1394 | 0.020 |
Why?
|
| CD5 Antigens | 1 | 2007 | 129 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 427 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2007 | 703 | 0.020 |
Why?
|
| Length of Stay | 1 | 2013 | 2006 | 0.020 |
Why?
|
| Mastectomy | 1 | 2011 | 1553 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 2233 | 0.010 |
Why?
|
| Cisplatin | 1 | 2010 | 2499 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2010 | 2105 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 2142 | 0.010 |
Why?
|
| Recurrence | 1 | 2010 | 4880 | 0.010 |
Why?
|
| Incidence | 1 | 2011 | 5841 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 3058 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2007 | 3042 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 9039 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 10267 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 9479 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 3189 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 6404 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 2805 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 22529 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 16720 | 0.000 |
Why?
|
| Animals | 1 | 2007 | 61554 | 0.000 |
Why?
|